Anti-IgE in allergic asthma and rhinitis: An update

Expert Opinion on Biological Therapy

Volumn 7, Issue 11, 2007, Pages 1739-1747

  Morjaria, Jaymin B ^a,b   Gnanakumaran, Gnanasekaran ^a,b   Babu, Kesavan Suresh ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Asthma; IgE; Omalizumab; Rhinitis

Indexed keywords

FLUTICASONE; IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO; ANTIASTHMATIC AGENT; MONOCLONAL ANTIBODY;

AIRWAY; ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; INFLAMMATION; PERENNIAL RHINITIS; QUALITY OF LIFE; REVIEW; IMMUNOLOGY; RHINITIS;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN E; RHINITIS;

EID: 36049024809     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.11.1739     Document Type: Review

References (53)

1. ARSHAD SH, HOLGATE S: The role of IgE in allergen-induced inflammation and the potential for intervention with a humanized monoclonal anti-IgE antibody. Clin. Exp. Allergy (2001) 31(9):1344-1351.
2. WALDMANN TA, IIO A, OGAWA M, MCINTYRE OR, STROBER W: The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma. J. Immunol. (1976) 117(4):1139-1144.
3. PARRAVICINI V, GADINA M, KOVAROVA M et al.: Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat. Immunol. (2002) 3(8):741-748.
4. BONNEFOY JY, LECOANET-HENCHOZ S, GAUCHAT JF et al.: Structure and functions of CD23. Int. Rev. Immunol. (1997) 16(1-2):113-128.
5. BOULET LP, CHAPMAN KR, COTE J et al.: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am. J. Respir. Crit. Care Med. (1997) 155(6):1835-1840.
6. FAHY JV, FLEMING HE, WONG HH et al.: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. (1997) 155(6):1828-1834.
7. MILGROM H, FICK RB Jr, SU JQ et al.: Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 study group. N. Engl. J. Med. (1999) 341(26):1966-1973.
8. BUSSE W, CORREN J, LANIER BQ et al.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the rreatment of severe allergic asthma. J. Allergy Clin. Immunol. (2001) 108(2):184-190.
9. MILGROM H, BERGER W, NAYAK A et al.: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics (2001) 108(2):E36.
10. SOLER M, MATZ J, TOWNLEY R et al.: The anti-IgE antibody omalizumab reduces exacerbarions and sreroid requirement in allergic asthmatics. Eur. Respir. J. (2001) 18(2):254-261.
11. FICK RB, ROHANE PW, GUPTA N et al: Anti-inflammatory effects of a recombinant monoclonal anti-IgE (E25) in asthma. Am. J. Respir. Crit. Care Med. (2000) 161:A199.
12. DJUKANOVIC R, WILSON SJ, KRAFT M et al.: Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. (2004) 170(6):583-593.
13. NOGA O, HANF G, BRACHMANN I et al.: Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J. Allergy Clin. Immunol. (2006) 117(6):1493-1499.
14. NOGA O, HANF G, KUNKEL G: Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int. Arch. Allergy Immunol. (2003) 131(1):46-52.
15. HENDELES L, KHAN Y, SPENCER T, SHUSTER J, CHESROWN S, MASSANARI M: The effect of omalizumab on airway hyperresponsiveness to adenosine in asthma patients with poor adherence to inhaled steroids. Am. J. Respir. Crit. Care Med. (2007) 175:A5.
16. BERGER P, SCOTTO-GOMEZ E, MOLIMARD M et al.: Omalizumab decreases nonspecific airway hyperresponsiveness in vitro. Allergy (2007) 62(2):154-161.
17. HOLGATE ST, CHUCHALIN AG, HEBERT J et al.: Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy (2004) 34(4):632-638.
18. BUHL R, SOLER M, MATZ J et al.: Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur. Respir. J. (2002) 20(1):73-78.
19. LANIER BQ, CORREN J, LUMRY W et al.: Omalizumab is effective in the long-term control of severe allergic asthma. Ann. Allergy Asthma Immunol. (2003) 91(2):154-159.
20. National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI)/World Health Organisation (WHO) workshop report: Global straregy for asthma management and prevention (2002):NIH Publication No. 02-3659.
21. HUMBERT M, BEASLEY R, AYRES J et al.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy (2005) 60(3):309-316.
22. AYRES JG, HIGGINS B, CHILVERS ER et al.: Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy (2004) 59(7):701-708.
23. National Institutes of Health, National Heart, Lung and Blood Institute. Expert panel report 2. Guidelines for the diagnosis and management of asthma. Betheseda (MD) (1997):NIH Publication No. 97-4051.
24. BOUSQUET J, AYRE G, BLOGG M: Omalizumab added to best standard care reduces exacerbations in patients with severe persistent asthma according to GINA 2002 classification. Eur. Respir. J. (2004) 24(Suppl. 48)(220S):P1390.
25. NIVEN R, CHUNG KF, PANAHLOO Z, BLOGG M, AYRE G: Omalizumab in patients with inadequately controlled severe persitent allergic (IgE-mediated) asthma: a subgroup analysis of an open label trial. Am. J. Respir. Crit. Care Med. (2007) 175:A28.
26. BOUSQUET J, WENZEL S, HOLGATE S et al.: Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest (2004) 125(4):1378-1386.
27. BOUSQUET J, CABRERA P, BERKMAN N et al.: The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy (2005) 60(3):302-308.
28. JUNIPER EF, GUYATT GH, EPSTEIN RS et al.: Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax (1992) 47(2):76-83.
29. JUNIPER EF, GUYATT GH, FERRIE PJ, GRIFFITH LE: Measuring quality of life in asthma. Am. Rev. Respir. Dis. (1993) 147(4):832-838.
30. GUYATT GH, JUNIPER EF, WALTER SD, GRIFFITH LE, GOLDSTEIN RS: Interpreting treatment effects in randomised trials. BMJ (1998) 316(7132):690- 693.
31. JUNIPER EF, GUYATT GH, WILLAN A, GRIFFITH LE: Determining a minimal important change in a disease-specific quality of life questionnaire. J. Clin. Epidemiol. (1994) 47(1):81-87.
32. CHIPPS B, CORREN J, FINN A, HEDGECOCK S, FOX H, BLOGG M: Omalizumab significantly improves quality of life in patients with severe persistent asthma. J. Allergy Clin. Immunol. (2005) 115(2):S5-S19.
33. FINN A, GROSS G, VAN BAVEL J et al.: Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J. Allergy Clin. Immunol. (2003) 111(2):278-284.
34. BOUSQUET J, VAN CAUWENBAGE P, KHALTAEY N: Allergic rhinitis and its impact on asthma (ARIA) workshop report. J. Allergy Clin. Immunol. (2001) 108(Suppl.):S147-S334.
35. JUNIPER EF, GUYATT GH: Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin. Exp. Allergy (1991) 21(1):77-83.
36. ADELROTH E, RAK S, HAAHTELA T et al.: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2000) 106(2):253-259.
37. CASALE TB, CONDEMI J, LAFORCE C et al.: Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA (2001) 286(23):2956-2967.
38. KUEHR J, BRAUBURGER J, ZIELEN S et al.: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2002) 109(2):274-280.
39. PORTNOY J, KING K, KANAREK H, HORNER S: Incidence of systemic reactions during rush immunotherapy. Ann. Allergy (1992) 68(6):493-498.
40. CASALE TB, BUSSE WW, KLINE JN et al.: Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2006) 117(1):134- 140.
41. CHERVINSKY P, CASALE T, TOWNLEY R et al.: Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. (2003) 91(2):160-167.
42. LEYNAERT B, NEUKIRCH F, DEMOLY P, BOUSQUET J: Epidemiologic evidence for asthma and rhinitis comorbidity. J. Allergy Clin. Immunol. (2000) 106(5 Suppl.):S201-S205.
43. YAWN BP, YUNGINGER JW, WOLLAN PC et al.: Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J. Allergy Clin. Immunol. (1999) 103(1 Part 1):54-59.
44. ADAMS RJ, FUHLBRIGGE AL, FINKELSTEIN JA, WEISS ST: Intranasal steroids and the risk of emergency department visits for asthma. J. Allergy Clin. Immunol. (2002) 109(4):636-642.
45. CRYSTAL-PETERS J, NESLUSAN C, CROWN WH, TORRES A: Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J. Allergy Clin. Immunol. (2002) 109(1):57-62.
46. VIGNOLA AM, HUMBERT M, BOUSQUET J et al.: Efficacy and tolerabiliry of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy (2004) 59(7):709-717.
47. WASSERFALLEN JB, GOLD K, SCHULMAN KA, BARANIUK JN: Development and validation of a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trials. J. Allergy Clin. Immunol. (1997) 100(1):16-22.
48. BOUSQUET J, VIGNOLA AM, DEMOLY P: Links between rhinitis and asthma. Allergy (2003) 58(8):691-706.
49. CRUZ AA, LIMA F, SARINHO E et al.: Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin. Exp. Allergy (2007) 37:197-207.
50. WALKER S, MONTEIL M, PHELAN K, LASSERSON TJ, WALTER EH: Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. (2006) 2:CD003559.
51. DREYFUS DH, RANDOLPH CC: Characterization of an anaphylactoid reaction to omalizumab. Ann. Allergy Asthma Immunol. (2006) 96(4):624-627.
52. CISTERNAS MG, BLANC PD, YEN IH: A comprehensive study of the direct and indirect costs of adult asthma. J. Allegy Clin. Immunol. (2003) 111:1212-1218.
53. OBA Y, SALZMAN GA: Cost effectiveness analysis of omalizumab in adults and adolescents with moderate to severe allergic asthma. J. Allegy Clin. Immunol. (2004) 114:265-269.